Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 745 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... January 28, 2022 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Cancer research could revive the UK’s ailing public finances November 16, 2022 Load more HOT NEWS FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... The Doctor Will See You Now…On the Screen 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales
